QA: Enliven Therapeutics Inc. in us_pharma/2021

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001672619_2022_Enliven_Therapeutics_Inc.pdf

Logs

warning Missing logo subcommand.report {}
info Failed to set obs_EconomicCapitalRatio industry.us_generic {'reason': "KeyError('0001672619')"}

Graph

Absolute values for 0001672619, Enliven Therapeutics Inc.

  xvar xval
0 AssetsCurrent 92,696,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 250,000
3 remainder_Assets 700,000
4 LiabilitiesCurrent 7,210,000
5 LiabilitiesNoncurrent 406,000
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 13,000,000
9 ResearchAndDevelopmentExpense 38,442,000
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome 58,000
13 remainder_ComprehensiveNetIncome -20,000
  yvar yval
0 Assets 93,646,000
1 Liabilities 7,616,000
2 Expenses 51,442,000
3 Revenues 0
4 StockholdersEquity 86,030,000
5 NetIncome -51,384,000
6 ComprehensiveNetIncome -51,394,000
7 BaseVar 76,391,000
8 EconomicCapitalRatio 1.91

Edgar->Model Mapping

Feature Distribution

Change over Time